• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 528-43-8 Price $30 / 20mg
    Catalog No.CFN98872Purity>=98%
    Molecular Weight266.3 Type of CompoundLignans
    FormulaC18H18O2Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universiti Kebangsaan Malaysia (Malaysia)
  • Universidad Miguel Hernández (Spain)
  • Instytut Nawozów Sztucznych w P... (Poland)
  • Sapienza University of Rome (Italy)
  • University of Fribourg (Switzerland)
  • Gyeongsang National University (Korea)
  • Mahidol University (Thailand)
  • University of Queensland (Australia)
  • Amity University (India)
  • Universiti Putra Malaysia(UPM) (Malaysia)
  • Siksha O Anusandhan University (India)
  • More...
  • Package
    Featured Products
    Deapi-platycodin D3

    Catalog No: CFN92269
    CAS No: 67884-05-3
    Price: $388/5mg
    Salvianolic acid B

    Catalog No: CFN99332
    CAS No: 115939-25-8
    Price: $80/20mg
    Ginsenoside Rh3

    Catalog No: CFN99972
    CAS No: 105558-26-7
    Price: $218/20mg
    Neocryptotanshinone II

    Catalog No: CFN92160
    CAS No: 27468-20-8
    Price: $536/5mg

    Catalog No: CFN92233
    CAS No: 550-43-6
    Price: $490/5mg
    Biological Activity
    Description: Magnolol is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively. Magnolol has antifungal, antibacterial, anti-oxidative, antidepressant-like, anti- tumor, and neuroprotective effects, it also prevents skin photoaging in UVB-irradiated hairless mice. Magnolol has a wide spectrum of targets including TNF-α, NF-KB, GSK3β.
    Targets: JNK | ERK | AP-1 | NF-kB | ROS | HO-1 | Nrf2 | MMP(e.g.TIMP) | Antifection | NOS | Akt | GSK-3 | PPARγ | COX | TNF-α | Bcl-2/Bax | cAMP | RXRα
    In vitro:
    J Nat Prod. 2015 Jan 23;78(1):61-8.
    Magnolol Inhibits RANKL-induced osteoclast differentiation of raw 264.7 macrophages through heme oxygenase-1-dependent inhibition of NFATc1 expression.[Pubmed: 25574844]
    Magnolol (1) isolated from Magnolia officinalis exhibits many beneficial effects such as anti-inflammatory and antioxidant activity. The aim of this study was to evaluate the effects of Magnolol (1) on RANKL-induced osteoclast differentiation and investigate the underlying molecular mechanisms.
    Treatment with Magnolol (1) significantly inhibited osteoclast differentiation of RAW 264.7 macrophages and bone-resorbing activity of osteoclasts in the RANKL-induced system. Moreover, RANKL-activated JNK/ERK/AP-1 and NF-κB signaling, ROS formation, and NFATc1 activation were attenuated by Magnolol (1). A novel finding of this study is that Magnolol (1) can increase heme oxygenase-1 (HO-1) expression and Nrf2 activation in RANKL-stimulated cells. Blocking HO-1 activity with tin protoporphyrin IX markedly reversed Magnolol (1)-mediated inhibition of osteoclast differentiation, NFATc1 nuclear translocation, and MMP-9 activity, suggesting that HO-1 contributes to the attenuation of NFATc1-mediated osteoclastogenesis by Magnolol (1). Therefore, the inhibitory effect of Magnolol (1) on osteoclast differentiation is due to inhibition of MAPK/c-fos/AP-1 and NF-κB signaling as well as ROS production and up-regulation of HO-1 expression, which ultimately suppresses NFATc1 induction.
    These findings indicate that Magnolol (1) may have potential to treat bone diseases associated with excessive osteoclastogenesis.
    Arch Pharm Res. 2000 Feb;23(1):46-9.
    Antifungal activity of magnolol and honokiol.[Pubmed: 10728656]
    Two neolignan compounds, Magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl, 1) and honokiol (5,5'-diallyl-2,4'-dihydroxybiphenyl, 2), were isolated from the stem bark of Magnolia obovata and evaluated for antifungal activity against various human pathogenic fungi.
    Compound 1 and 2 showed significant inhibitory activities against Trichophyton mentagrophytes, Microsporium gypseum, Epidermophyton floccosum, Aspergillus niger, Cryptococcus neoformans, and Candida albicans with minimum inhibitory concentrations (MIC) in a range of 25-100 microg/ml.
    Therefore, compound 1 and 2 could be used as lead compounds for the development of novel antifungal agents.
    Eur J Pharmacol. 2004 Aug 2;496(1-3):189-95.
    In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp.[Pubmed: 15288590]
    Honokiol and Magnolol, two major phenolic constituents of Magnolia sp., have been known to exhibit antibacterial activities. However, until now, their antibacterial activity against Propionibacterium sp. has not been reported.
    To this end, the antibacterial activities of honokiol and Magnolol were detected using the disk diffusion method and a two-fold serial dilution assay. Honokiol and Magnolol showed strong antibacterial activities against both Propionibacterium acnes and Propionibacterium granulosum, which are acne-causing bacteria. The minimum inhibitory concentrations (MIC) of honokiol and Magnolol was 3-4 microg/ml (11.3-15 microM) and 9 microg/ml (33.8 microM), respectively. In addition, the killing curve analysis showed that Magnolol and honokiol killed P. acnes rapidly, with 10(5) organisms/ml eliminated within 10 min of treatment with either 45 microg (169.2 microM) of Magnolol or 20 microg (75.2 microM) of honokiol per ml. The cytotoxic effect of honokiol and Magnolol was determined by a colorimetric (3-(4,5-dimetyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (MTT) assay using two animal cell lines, human normal fibroblasts and HaCaT. In this experiment, Magnolol exhibited lower cytotoxic effects than honokiol at the same concentration, but they showed similar cytotoxicity when triclosan was employed as an acne-mitigating agent. In addition, they reduced secretion of interleukin-8 and tumor necrosis factor alpha (TNF-alpha) induced by P. acnes in THP-1 cells indicating the anti-inflammatory effects of them. When applied topically, neither phenolic compound induced any adverse reactions in a human skin primary irritation test.
    Therefore, based on these results, we suggest the possibility that Magnolol and honokiol may be considered as attractive acne-mitigating candidates for topical application.
    In vivo:
    Toxicol Appl Pharmacol. 2014 Sep 15;279(3):294-302.
    Magnolol protects neurons against ischemia injury via the downregulation of p38/MAPK, CHOP and nitrotyrosine.[Pubmed: 25038313]
    Magnolol is isolated from the herb Magnolia officinalis, which has been demonstrated to exert pharmacological effects. Our aim was to investigate whether Magnolol is able to act as an anti-inflammatory agent that brings about neuroprotection using a global ischemic stroke model and to determine the mechanisms involved.
    Rats were treated with and without Magnolol after ischemia reperfusion brain injury by occlusion of the two common carotid arteries. The inflammatory cytokine production in serum and the volume of infarction in the brain were measured. The proteins present in the brains obtained from the stroke animal model (SAM) and control animal groups with and without Magnolol treatment were compared. Magnolol reduces the total infarcted volume by 15% and 30% at dosages of 10 and 30mg/kg, respectively, compared to the untreated SAM group. The levels of acute inflammatory cytokines, including interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6 were attenuated by Magnolol. Magnolol was also able to suppress the production of nitrotyrosine, 4-hydroxy-2-nonenal (4-HNE), inducible NO synthase (iNOS), various phosphorylated p38 mitogen-activated protein kinases and various C/EBP homologues. Furthermore, this modulation of ischemia injury factors in the SAM model group treated with Magnolol seems to result from a suppression of reactive oxygen species production and the upregulation of p-Akt and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
    These findings confirm the anti-oxidative properties of Magnolol, including the inhibition of ischemic injury to neurons; this protective effect seems to involve changes in the in vivo activity of Akt, GSK3β and NF-κB.
    Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):715-25.
    Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents.[Pubmed: 18093712 ]
    Honokiol and Magnolol are the main constituents simultaneously identified in the barks of Magnolia officinalis, which have been used in traditional Chinese medicine to treat a variety of mental disorders including depression. In the present study, we reported on the antidepressant-like effects of oral administration of the mixture of honokiol and Magnolol in well-validated models of depression in rodents: forced swimming test (FST), tail suspension test (TST) and chronic mild stress (CMS) model.
    The mixture of honokiol and Magnolol significantly decreased immobility time in the mouse FST and TST, and reversed CMS-induced reduction in sucrose consumption to prevent anhedonia in rats. However, this mixture was unable to affect ambulatory or rearing behavior in the mouse open-field test. CMS induced alterations in 5-hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) levels in various brain regions of rats. An increase in serum corticosterone concentrations and a reduction in platelet adenylyl cyclase (AC) activity were simultaneously found in the CMS rats. The mixture of honokiol and Magnolol at 20 and 40 mg/kg significantly attenuated CMS-induced decreases of 5-HT levels in frontal cortex, hippocampus, striatum, hypothalamus and nucleus accumbens. And it markedly increased 5-HIAA levels in frontal cortex, striatum and nucleus accumbens at 40 mg/kg and in frontal cortex at 20 mg/kg in the CMS rats. A subsequent reduction in 5-HIAA/5-HT ratio was found in hippocampus and nucleus accumbens in the CMS rats receiving this mixture. Furthermore, the mixture of honokiol and Magnolol reduced elevated corticosterone concentrations in serum to normalize the hypothalamic-pituitary-adrenal (HPA) hyperactivity in the CMS rats. It also reversed CMS-induced reduction in platelet AC activity, via upregulating the cyclic adenosine monophosphate (cAMP) pathway. These results suggested that the mixture of honokiol and Magnolol possessed potent antidepressant-like properties in behaviors involved in normalization of biochemical abnormalities in brain 5-HT and 5-HIAA, serum corticosterone levels and platelet AC activity in the CMS rats.
    Our findings could provide a basis for examining directly the interaction of the serotonergic system, the HPA axis and AC-cAMP pathway underlying the link between depression and treatment with the mixture of honokiol and Magnolol.
    Magnolol Description
    Source: The barks of Magnolia officinalis
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN95007
    CAS No: 135309-02-3
    Price: $418/5mg
    Magnolignan A

    Catalog No: CFN96188
    CAS No: 93673-81-5
    Price: $388/5mg

    Catalog No: CFN90185
    CAS No: 3804-70-4
    Price: $268/20mg
    Kobophenol A

    Catalog No: CFN92530
    CAS No: 124027-58-3
    Price: $318/10mg

    Catalog No: CFN95054
    CAS No: 83864-78-2
    Price: $388/5mg
    Ganoderic acid G

    Catalog No: CFN90801
    CAS No: 98665-22-6
    Price: $463/10mg
    Secologanic acid

    Catalog No: CFN95028
    CAS No: 60077-46-5
    Price: $318/10mg
    Vicenin -1

    Catalog No: CFN92030
    CAS No: 35927-38-9
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.7552 mL 18.7758 mL 37.5516 mL 75.1033 mL 93.8791 mL
    5 mM 0.751 mL 3.7552 mL 7.5103 mL 15.0207 mL 18.7758 mL
    10 mM 0.3755 mL 1.8776 mL 3.7552 mL 7.5103 mL 9.3879 mL
    50 mM 0.0751 mL 0.3755 mL 0.751 mL 1.5021 mL 1.8776 mL
    100 mM 0.0376 mL 0.1878 mL 0.3755 mL 0.751 mL 0.9388 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Cell Research:
    Biol Pharm Bull. 2006 Dec;29(12):2498-501.
    Magnolol-induced apoptosis is mediated via the intrinsic pathway with release of AIF from mitochondria in U937 cells.[Pubmed: 17142989]
    Magnolol has been reported to have an inhibitory effect on tumor invasion in vitro and in vivo.
    In this study, we found that treatment with 30 microM Magnolol exhibited growth inhibition partly by inducing apoptosis in cultured human leukemia U937 cells and that the apoptosis was induced via the sequential ordering of molecular events; 1) a transient decrease of phosphorylated extracelluar signal-requlated kinase (ERK), 2) translocation of apoptosis inducing factor (AIF) from mitochondria to cytosol concurrent with a decreased membrane potential, and 3) downregulation of bcl-2 protein. Pretreatment of the cells with a pan-caspase inhibitor Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK) did not prevent the apoptosis induced by Magnolol.
    These findings indicated that the above-mentioned sequence of intracellular signaling events led to apoptosis in Magnolol-treated U937 cells, which was caspase-independent.
    Eur J Pharmacol. 2006 May 10;537(1-3):64-9.
    Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage.[Pubmed: 16631734]
    The aim of the present study was to investigate the neuroprotective effects of honokiol and Magnolol, two major bioactive constituents of the bark of Magnolia officinalis, against neuron toxicity induced by glucose deprivation, excitatory amino acids and hydrogen peroxide (H(2)O(2)) in cultured rat cerebellar granule cells.
    Cell membrane damage was measured with a lactate dehydrogenase (LDH) release assay and 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was used to assess mitochondrial activity, reflecting cell survival. Results showed that honokiol and Magnolol alone did not affect mitochondrial function and cell damage, but significantly reversed glucose deprivation-induced mitochondrial dysfunction and cell damage. The glutamate receptor blocker MK-801 and antioxidant vitamin E also provided protection against this damage. Furthermore, honokiol was more potent than Magnolol in protecting against glutamate-, N-methyl-D-aspartate (NMDA)- and H(2)O(2)-induced mitochondrial dysfunction.
    These results demonstrated that the neuroprotective effects of honokiol and Magnolol may be related to their anti-oxidative actions and antagonism of excitotoxicity induced by excitatory amino acids, suggesting that both compounds may be potential therapeutic agents for neurodegenerative diseases.
    Animal Research:
    Int Immunopharmacol. 2015 Jun 10. pii: S1567-5769(15)00289-1.
    Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR-γ-dependent inhibition of NF-kB activation.[Pubmed: 26072062]
    Acute lung injury (ALI) has a high morbidity and mortality rate due to the serious inflammation and edema occurred in lung. Magnolol extracted from Magnolia officinalis, has been reported to exhibit anti-inflammatory, and antioxidant activities. Peroxisome proliferator-activated receptors (PPARs) are known to exert a cytoprotective effect against cellular inflammatory stress and oxidative injury. The aim of this study was to explore the involvement of PPAR-γ in the beneficial effect of Magnolol in lipopolysaccharide (LPS)-induced ALI.
    We found that treatment with Magnolol greatly improved the pathological features of ALI evidenced by reduction of lung edema, polymorphonuclear neutrophil infiltration, ROS production, the levels of pro-inflammatory cytokines in bronchoalveolar lavage fluid (BALF), the expression of iNOS and COX-2, and NF-κB activation in lungs exposed to LPS. Importantly, Magnolol is capable of increasing the PPAR-γ expression and activity in lungs of ALI. However, blocking PPAR-γ activity with GW9662 markedly abolished the protective and anti-inflammatory effects of Magnolol.
    Taken together, the present study provides a novel mechanism accounting for the protective effect of Magnolol in LPS-induced ALI is at least partly attributed to induction of PPAR-γ in lungs, and in turn suppressing NF-κB-related inflammatory responses.
    Environ Toxicol Pharmacol. 2015 Jan;39(1):417-23.
    Magnolol reduces UVB-induced photodamage by regulating matrix metalloproteinase activity.[Pubmed: 25562310]
    In this study, we evaluated the anti-photoaging activity of Magnolol in UV-irradiated hairless mice, and hypothesized that Magnolol would prevent photoaging in these animals. The inhibitory effect of Magnolol on wrinkle formation was determined by analyzing the skin replica, histologically examining the epidermal thickness, and identifying damage to the collagen fibers.
    The protective effects of Magnolol on UVB-induced skin photoaging were examined by determining the level of MMPs and mitogen-activated protein kinases (MAPKs). Exposure to UVB radiation significantly increased skin thickness and wrinkle grade, but Magnolol treatment significantly reduced the average length and depth of wrinkles, and this was correlated with the inhibition of collagen fiber loss. The Magnolol-treated group had remarkably decreased activity levels of MMP-1, -9, and -13 compared to the corresponding levels in the vehicle-treated UVB-irradiated group.
    These results indicate that Magnolol prevents skin photoaging in UVB-irradiated hairless mice.